In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Neos Therapeutics Inc. (NASDAQ:NEOS) reported that Dammeyer Rodney F has picked up 1,001,568 of common stock as of 2017-04-14.

The acquisition brings the aggregate amount owned by Dammeyer Rodney F to a total of 1,001,568 representing a 6.2% stake in the company.

For those not familiar with the company, Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

A glance at Neos Therapeutics Inc. (NASDAQ:NEOS)’s key stats reveals a current market capitalization of 152.29 Million based on 22.56 Million shares outstanding and a price at last close of $6.80 per share.

Looking at insider activity, there are a few transactions worth noting.

Specifically, on 2016-08-31, Fong picked up 1,500 at a purchase price of $6.54. This brings their total holding to 1,500 as of the date of the filing.

On the sell side, the most recent transaction saw Presidio unload 213 shares at a sale price of $9.88. This brings their total holding to 39,998.

It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Neos Therapeutics Inc. (NASDAQ:NEOS) as things move forward to see if its progress aligns with these transactions.

Subscribe below and we’ll keep you on top of what’s happening before it moves markets.